ATE357537T1 - Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren - Google Patents

Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren

Info

Publication number
ATE357537T1
ATE357537T1 AT00982313T AT00982313T ATE357537T1 AT E357537 T1 ATE357537 T1 AT E357537T1 AT 00982313 T AT00982313 T AT 00982313T AT 00982313 T AT00982313 T AT 00982313T AT E357537 T1 ATE357537 T1 AT E357537T1
Authority
AT
Austria
Prior art keywords
methods
gene
cell
target gene
molecule
Prior art date
Application number
AT00982313T
Other languages
English (en)
Inventor
Matthew Ashby
Daniel D Shoemaker
Original Assignee
Rosetta Inpharmatics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics Llc filed Critical Rosetta Inpharmatics Llc
Application granted granted Critical
Publication of ATE357537T1 publication Critical patent/ATE357537T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00982313T 1999-12-03 2000-11-30 Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren ATE357537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,889 US6518035B1 (en) 1998-06-02 1999-12-03 Targeted methods of drug screening using co-culture methods

Publications (1)

Publication Number Publication Date
ATE357537T1 true ATE357537T1 (de) 2007-04-15

Family

ID=23806481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982313T ATE357537T1 (de) 1999-12-03 2000-11-30 Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren

Country Status (9)

Country Link
US (1) US6518035B1 (de)
EP (1) EP1235935B1 (de)
JP (1) JP4718082B2 (de)
AT (1) ATE357537T1 (de)
AU (1) AU1936301A (de)
CA (1) CA2393360C (de)
DE (1) DE60034059T2 (de)
ES (1) ES2283334T3 (de)
WO (1) WO2001040518A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE516497T1 (de) * 2000-03-06 2011-07-15 Asterand Acquisition Llc Screening für funktionshomologien
AU2001270126A1 (en) * 2000-06-23 2002-01-08 Cytokinetics, Inc. Image analysis for phenotyping sets of mutant cells
AU2002303645A1 (en) * 2001-05-04 2002-11-18 Axiom Biotechnologies, Inc. Matrix assays in genomically indexed cells
US6894205B2 (en) * 2001-06-22 2005-05-17 Vanderbilt University Assay for toxin induced neuronal degeneration and viability in C. elegans
US6977152B2 (en) * 2001-09-07 2005-12-20 Virtual Arrays, Inc. Biological assays using coded RNA reporters
US20030069256A1 (en) * 2001-09-25 2003-04-10 Torrance Christopher J. Use of isogenic human cancer cells for high-throughput screening and drug discovery
US7794967B2 (en) 2001-11-21 2010-09-14 Bioimics Ab Method and kit for detection of novel pathogen inhibitors
DE10261834A1 (de) * 2002-12-20 2004-07-08 Phenion Gmbh & Co. Kg Hochdurchsatz-geeignetes Screening-Verfahren zur Identifikation von Wirkstoffen
WO2005020886A2 (en) * 2003-06-27 2005-03-10 New England Biolabs, Inc. Identification and use of cofactor independent phosphoglycerate mutase as a drug target
GB2423988A (en) * 2003-07-18 2006-09-13 Cytokinetics Inc Characterizing biological stimuli by response curves
US7150969B2 (en) * 2004-06-04 2006-12-19 Rosetta Inpharmatics Llc Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2)
EP3029135B1 (de) 2005-07-07 2021-03-17 The Regents of the University of California Vorrichtung für zellkultur-array
US8257964B2 (en) 2006-01-04 2012-09-04 Cell ASIC Microwell cell-culture device and fabrication method
US9388374B2 (en) 2005-07-07 2016-07-12 Emd Millipore Corporation Microfluidic cell culture systems
US9637715B2 (en) 2005-07-07 2017-05-02 Emd Millipore Corporation Cell culture and invasion assay method and system
US9354156B2 (en) 2007-02-08 2016-05-31 Emd Millipore Corporation Microfluidic particle analysis method, device and system
US7745209B2 (en) 2005-07-26 2010-06-29 Corning Incorporated Multilayered cell culture apparatus
US7745210B2 (en) * 2006-06-30 2010-06-29 Corning Incorporated Fluid flow diverter for cell culture vessel
WO2008073900A1 (en) * 2006-12-08 2008-06-19 Worcester Polytechnic Institute (Wpi) Targets, including yap1, for antifungal drug discovery and therapy
US7897379B2 (en) * 2007-02-26 2011-03-01 Corning Incorporated Device and method for reducing bubble formation in cell culture
US9309491B2 (en) * 2007-05-29 2016-04-12 Corning Incorporated Cell culture apparatus for co-culture of cells
GB2451287A (en) * 2007-07-26 2009-01-28 Envirogene Ltd Identification of hydrocarbon deposits through detection of a microbial polynucleotide
EP3173787B1 (de) 2008-01-03 2021-06-02 EMD Millipore Corporation Zellkultur-array-system für automatisierte assays und verfahren zum betrieb und dessen herstellung
US9353342B2 (en) 2010-01-21 2016-05-31 Emd Millipore Corporation Cell culture and gradient migration assay methods and devices
US10526572B2 (en) 2011-04-01 2020-01-07 EMD Millipore Corporaticn Cell culture and invasion assay method and system
CN107345204B (zh) 2011-12-03 2021-02-12 Emd密理博公司 用于微流体细胞培养的微型培育系统和方法
US20180327806A1 (en) * 2015-11-04 2018-11-15 The Broad Institute, Inc. Multiplex high-resolution detection of micro-organism strains, related kits, diagnostics methods and screening assays
KR102127949B1 (ko) * 2018-11-16 2020-06-29 충북대학교 산학협력단 Erg11 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
EP4022307A1 (de) * 2019-09-24 2022-07-06 Université de Genève Verfahren zur unabhängigen analyse mehrerer biologischer prozesse in eingekapselten 3d-zell-co-kulturen
CN113130000B (zh) * 2021-03-22 2022-09-16 同济大学 一种青蒿素抗疟作用靶基因的筛选方法
WO2023004149A1 (en) * 2021-07-23 2023-01-26 The Regents Of The University Of California Methods and model systems for assessing therapeutic properties of candidate agents and related computer readable media and systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980281A (en) 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
WO1995006132A2 (en) 1993-08-27 1995-03-02 Myco Pharmaceuticals, Incorporated Identifying biologically active agents through culture color change
EP0679716A4 (de) 1993-11-12 1999-06-09 Kenichi Matsubara Genetische Signaturen.
JP2002509428A (ja) 1996-08-07 2002-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ａｆｃ１およびｒｃｅ１：イソプレニル化されたｃａａｘプロセシング酵素
WO1998054333A2 (en) 1997-06-02 1998-12-03 Acacia Biosciences Inc. Mammalian caax processing enzymes
CA2234402A1 (en) 1997-06-24 1998-12-24 Smithkline Beecham Corporation Human rce1
CA2234418A1 (en) 1997-06-24 1998-12-24 Smithkline Beecham Corporation Human afc1
US6046002A (en) 1998-01-05 2000-04-04 The Board Of Trustees Of The Leland Stanford Junior University Highly parallel and sensitive method for identifying drugs and drug targets

Also Published As

Publication number Publication date
AU1936301A (en) 2001-06-12
DE60034059T2 (de) 2007-12-13
JP4718082B2 (ja) 2011-07-06
CA2393360A1 (en) 2001-06-07
WO2001040518A1 (en) 2001-06-07
ES2283334T3 (es) 2007-11-01
JP2003517308A (ja) 2003-05-27
CA2393360C (en) 2013-01-08
EP1235935A4 (de) 2004-10-20
EP1235935B1 (de) 2007-03-21
EP1235935A1 (de) 2002-09-04
US6518035B1 (en) 2003-02-11
DE60034059D1 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
ATE357537T1 (de) Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren
Brosh et al. A versatile platform for locus-scale genome rewriting and verification
Reina-Campos et al. Tissue-resident memory CD8 T cell diversity is spatiotemporally imprinted
Hosokawa et al. Bcl11b sets pro-T cell fate by site-specific cofactor recruitment and by repressing Id2 and Zbtb16
Feldman et al. Pooled genetic perturbation screens with image-based phenotypes
Bogdanović et al. Dynamics of enhancer chromatin signatures mark the transition from pluripotency to cell specification during embryogenesis
Yawata et al. Competition–dispersal tradeoff ecologically differentiates recently speciated marine bacterioplankton populations
Dahabieh et al. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB
Tabach et al. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation
Imai et al. Heterochromatin islands and their dynamic reorganization: a hypothesis for three distinctive features of cellular aging
DE60232059D1 (de) Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
EP1456346A4 (de) Neues induzierbares genexpressionssystem auf ecdysonrezeptor/invertebraten-retinoid-x-rezeptor-basis
Borok et al. Dissecting the regulatory switches of development: lessons from enhancer evolution in Drosophila
IL157756A (en) Methods for assaying activity of trancriptional control elements
Rendueles et al. Evolution by flight and fight: diverse mechanisms of adaptation by actively motile microbes
Guckelberger et al. Cohesin-mediated 3D contacts tune enhancer-promoter regulation
Maier et al. Searching novel clock genes using RNAi-based screening
Tajonar et al. Brief report: VGLL4 is a novel regulator of survival in human embryonic stem cells
Russ et al. Active maintenance of CD8+ T cell naivety through regulation of global genome architecture
Zhou et al. Frequency and distribution of AP-1 sites in the human genome
Venema et al. A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPs
Sène et al. Comparative transcriptomic analyses of a vero cell line in suspension versus adherent culture conditions
Fardoos et al. HIV specific CD8+ TRM-like cells in tonsils express exhaustive signatures in the absence of natural HIV control
Gu et al. Establishment and characterization of an immortalized renal cell line of the Chinese tree shrew (Tupaia belangeri chinesis)
Saunders et al. A platform for multimodal in vivo pooled genetic screens reveals regulators of liver function

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties